Lysozyme Chloride
drug drugOn this page
Also known as AcdeamAntalzymeImmunozimaLanzymeLeftoseLikinozymLisozimaLysozyme hydrochlorideMuramidase hclMuramidase hydrochlorideMurazymeNeutaseNeuzymeToyolysom-ds
Summary
Lysozyme Chloride (CHEMBL2107935) is a phase-3 clinical-stage unknown; indicated across 1 condition.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 1 condition
- Clinical trials: 1
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2107935 |
| Name | Lysozyme Chloride |
| Type | Unknown |
| Max phase | 3 |
Also known as: Acdeam, Antalzyme, Immunozima, Lanzyme, Leftose, Likinozym, Lisozima, Lysozyme chloride, Lysozyme hydrochloride, Muramidase hcl, Muramidase hydrochloride, Murazyme
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01645800 | PHASE4 | COMPLETED | Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.